NCT01924793 arm group 37f771ff3c53c8ac33e0649d55569c38 [clinicaltrials_resource:NCT01924793/arm-group/37f771ff3c53c8ac33e0649d55569c38]
DAS181-F02 Dry Powder in Bulk [clinicaltrials_resource:bb4a9fbaaf13c51fdf88213df3a47b92]An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection [clinicaltrials:NCT01924793]
arm group [clinicaltrials_vocabulary:arm-group]
NCT01924793 arm group 37f771ff3c53c8ac33e0649d55569c38 [clinicaltrials_resource:NCT01924793/arm-group/37f771ff3c53c8ac33e0649d55569c38]
Bio2RDF identifier
NCT01924793/arm-group/37f771ff3c53c8ac33e0649d55569c38
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... f771ff3c53c8ac33e0649d55569c38
description [clinicaltrials_vocabulary:description]
The DAS181-F02 nebulized formu ...... lized formulation instruction.
identifier
clinicaltrials_resource:NCT01924793/arm-group/37f771ff3c53c8ac33e0649d55569c38
title
NCT01924793 arm group 37f771ff3c53c8ac33e0649d55569c38
@en
type
label
NCT01924793 arm group 37f771ff ...... 771ff3c53c8ac33e0649d55569c38]
@en